> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Alkermes Stops Reporting Avadel's Profit After Its $2.3 Billion Deal, Calling It Impracticable
- URL: https://www.bullished.co/alkermes-stops-reporting-avadels-profit-after-its-2-3-billion-deal-calling-it-76743f75/
- Published: 2026-11-03T14:36:19.000Z
- Updated: 2026-11-03T14:36:19.000Z
- Description: The drugmaker's latest quarterly report says Avadel's stand-alone net income can no longer be presented, while LUMRYZ sales reached $226.0 million.
- Author: Matteo Parrino
- Tags: Earnings, ALKS, Industry: Healthcare

[Alkermes](https://www.bullished.co/tag/alks/), the Dublin-based drugmaker that develops medicines for brain and nervous system diseases, no longer shows what Avadel earns on its own. Its [10-Q quarterly report](https://www.sec.gov/Archives/edgar/data/0001520262/000119312526444507/alks-20260930.htm?ref=bullished.co) calls presenting Avadel's net income "impracticable" because the operations were folded in shortly after the February 12, 2026 closing.

## From a stated profit to revenue only

The company says Avadel and Alkermes no longer operate as separate entities inside its organizational structure. The 10-Q gives only LUMRYZ revenue: $89.9 million for the third quarter and $226.0 million for the first nine months.

The [prior quarterly filing](https://www.sec.gov/Archives/edgar/data/0001520262/000119312526319022/alks-20260630.htm?ref=bullished.co) had given Avadel's results: a $2.7 million net loss for the three months and $13.6 million of net income for six months, on revenue of $96.6 million and $136.1 million. LUMRYZ revenue was lower in the third quarter than the $96.6 million of the second.

In the [earnings release](https://www.sec.gov/Archives/edgar/data/0001520262/000119312526444381/alks-ex99%5F1.htm?ref=bullished.co) issued the same day, Alkermes said about 4,100 patients were on LUMRYZ at the end of the quarter.

## What the purchase left on the balance sheet

Alkermes paid total preliminary consideration of $2,306,920 thousand for Avadel. The balance sheet now carries $1,741.8 million of net intangibles, $592.5 million of goodwill and $136.9 million of contingent consideration.

The purchase price allocation is still preliminary, and the company expects to finish it no later than one year from the closing date. A contingent value right could pay former Avadel holders up to $165.7 million; the company expects that milestone to be determined by the end of 2027.

The deal's weight shows in earnings. Alkermes posted net income of $16.3 million for the third quarter but a nine-month net loss of $49.7 million, against $192.3 million of income a year earlier. Nine-month interest expense was $74.4 million, and $72.4 million of inventory step-up, a non-cash charge, ran through cost of goods.

## Cheaper debt, with a cap on rates

Alkermes financed the deal with term loans. An August amendment cut the spread on the term loan A facility by 0.75 percentage points and on the term loan B facility by 0.50 percentage points.

In October it entered two zero-cost interest rate collars, each covering $375.0 million, with a Term SOFR cap of 5.25%. The company said they limit its exposure to swings in the benchmark rate on its variable-rate debt.

The CVR payout of up to $165.7 million depends on a milestone the company expects to be determined by the end of 2027.

### Sources

- [10-Q Filing — Alkermes (ALKS)](https://www.sec.gov/Archives/edgar/data/0001520262/000119312526444507/alks-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Alkermes (ALKS), Q2 FY2026 filed 2026-07-28 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001520262/000119312526319022/alks-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, alks-ex99\_1.htm) — Alkermes, filed 2026-11-03](https://www.sec.gov/Archives/edgar/data/0001520262/000119312526444381/alks-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Alkermes: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/alkermes-q3-earnings-snapshot-121224942.html?ref=bullished.co) — Associated Press
- [Alkermes GAAP EPS of $0.09 beats by $0.15, revenue of $480.1M beats by $16.62M (ALKS:NASDAQ)](https://seekingalpha.com/news/4663299-alkermes-gaap-eps-of-0%5F09-beats-by-0%5F15-revenue-of-480%5F1m-beats-by-16%5F62m?ref=bullished.co) — seekingalpha.com
- [Alkermes: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/alkermes-q3-earnings-snapshot/616-73f06325-4655-4c48-98f5-9ce7b078b176?ref=bullished.co) — Associated Press
- [Alkermes: Q3 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/alkermes-q3-earnings-snapshot/616-73f06325-4655-4c48-98f5-9ce7b078b176?ref=bullished.co) — Associated Press
- [Alkermes (ALKS) Starts Phase 2 MDD Trial, Is The Upside Already Priced In?](https://finance.yahoo.com/healthcare/articles/alkermes-alks-starts-phase-2-061540353.html?ref=bullished.co) — Yahoo Finance

### More on Alkermes

- [Alkermes Third-Quarter Revenue Hits $480.1 Million, But Net Income Falls To $16.3 Million](https://www.bullished.co/alkermes-third-quarter-revenue-hits-480-1-million-but-net-income-falls-to-16-3-million-462a824c/)
- [Alkermes CEO Says A Small Miss In Sleep-Disorder Trial Wouldn't End Orexin Drug, If Signal Holds](https://www.bullished.co/alkermes-ceo-says-a-small-miss-in-sleep-disorder-trial-wouldnt-end-orexin-drug-if-signal-5602e615/)

[All Alkermes (ALKS) coverage →](https://www.bullished.co/tag/alks/)